Chemical formula: C₆H₆N₂O₃ Molecular mass: 154.125 g/mol PubChem compound: 5310993
Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C10AD06 | Acipimox | C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AD Nicotinic acid and derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| OLBETAM Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Acipimox is an active ingredient of these brands:
New Zealand (NZ)Singapore (SG)South Africa (ZA)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
